P31 Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 2000 1 Year 0.00 0.00
52 Week High 0.54
52 Week Low 0.38
P31 Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
SGX Singapore Most Active Stocks
N21 0.18 0.00%
H27 0.01 0.00%
5DE 0.02 0.00%
576 0.15 0.00%
Q01 1.24 0.81%
EG0 0.03 0.00%
B22 0.09 0.00%
FQ7 0.01 -50.00%
5DN 0.05 0.00%
C68 0.07 -12.50%
SGX Singapore Top Gainers Stocks
A6F 0.24 2300.00%
C11 0.12 1100.00%
A69 0.09 800.00%
T16 0.19 533.33%
A10 0.04 300.00%
L05 0.04 300.00%
D2V 0.06 100.00%
D2V 0.06 100.00%
L18 0.02 100.00%
A13 0.04 100.00%
SGX Singapore Top Losers Stocks
5BM 0.01 -90.91%
P82 0.01 -87.50%
B2X 0.04 -83.33%
B2X 0.04 -83.33%
FQ7 0.01 -50.00%
A54 0.07 -46.15%
F18 0.03 -40.00%
A18 0.09 -35.71%
C37 0.02 -33.33%
5NF 0.11 -26.67%

Pharmesis International Ltd (SGX: P31)

P31 Technical Analysis 3
As on 25th Aug 2015 P31 Share Price closed @ 0.04 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.04 & Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
P31 Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
P31 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.pharmesis.com
P31 Address
No. 8 Yingbin Road
P31 Latest News
Market highlights   The Straits Times   - 16th Aug 16
Pharmesis International issues profit guidance<PHAR.SI>   Reuters Key Development   - 05th Aug 16
Pharmesis International says Jiang Yun has been appointed as CEO<PHAR.SI>   Reuters Key Development   - 01st Jul 16
Is ArcelorMittal's 2016 Earnings Guidance Conservative?   Yahoo Finance UK   - 11th May 16
Shell's 1Q16 Earnings Slump but Beat Estimates   Yahoo Finance UK   - 06th May 16
Pharmesis International Ltd says monetary authority of Singapore has taken civil penalty action against director   Reuters Key Development   - 04th May 16
Healthcare stocks in the pink   AsiaOne   - 06th Jun 15
Pharmesis International Ltd announces appointment of Executive Chairman   Reuters Key Development   - 15th Jan 15
Research and Markets: Singapore Pharmaceutical Industry: The Pharmaceutical ...   Business Wire (press release)   - 09th Oct 12
Interactive Technical Analysis Chart Pharmesis International Ltd ( P31 SGX Singapore )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pharmesis International Ltd
P31 Business Profile
Pharmesis International Ltd., an investment holding company, develops, manufactures, and sells western medicines, health tonic products, and traditional Chinese medicine (TCM) formulated products in the People’s Republic of China. The company operates through Western Drugs, TCM Formulated Drugs, and Distribution segments. It is also involved in the wholesale of chemical drugs, biological raw products, TCMs, antibiotics, and antibiotics agents. The company offers its western medicines and TCM formulated products in the form of tablets, granules, pills, etc. Its products comprise Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi tablets for the treatment of flatus, inappetency, dyspepsy, and spleen weakness; and LianPu ShuangQing for the treatment of acute inflammation, such as dysentery and intestinal infection. Pharmesis International Ltd. also offers Shulinghou tablets, which clear heat and regenerate body fluid, as well as for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Er Ding granules for the treatment of jaundice, as well as clears heat toxics; and AFenKa for the treatment of migrane, pain, headache, cold, nasosinusitis, muscle pain, menstrual pain, toothache, and arthritis. In addition, the company provides Wuling Jiao Nang granules, which disperse water accumulation, regulate water circulation, and dispel dampness; Bear Bile and Bulbus Fritillariae oral liquid for the treatment of phlegmheat cough; and Gansu for the treatment of acute and chronic hepatitis. Pharmesis International Ltd. markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to approximately 2,000 hospitals through its sales and marketing personnel. The company was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.